Stock FEMY FEMASYS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Femasys Inc.

Equities

FEMY

US31447E1055

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.27 USD -4.51% Intraday chart for Femasys Inc. -3.79% +30.26%
Apr. 01 HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating MT
Mar. 28 Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives
AQ
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
GL
HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating
MT
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
GL
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
AQ
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility
AQ
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
GL
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
GL
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
AQ
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility
CI
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
GL
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
GL
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
CI
Femasys FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
AQ
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
GL
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
AQ
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
GL
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer
CI
Femasys Begins Patient Enrollment for Permanent Birth Control Candidate Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FEMY Stock
  4. News Femasys Inc.